In the phase III ADRIATIC trial, Imfinzi (durvalumab) showed a statistically significant and clinically meaningful improvement in overall survival and progression-free survival for patients with limited-stage small cell lung cancer who had not progressed following concurrent chemoradiotherapy, compared to placebo after cCRT.
A multidisciplinary team of experts in lung cancer screening and implementation science from the UCLA Health Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine at UCLA, and the UCLA Fielding School of Public Health, was awarded a $2.5 million grant from the Bristol Myers Squibb Foundation, an independent charitable organization, to spearhead a new initiative aimed at reducing disparities in lung cancer screening across Los Angeles County.
